San Diego, CA (PRWEB) April 28, 2013
Resource4thePeople announced today that it is following up on the recent warning issued by the Food and Drug Administration concerning alleged links between the popular antibiotic Zithromax and the risk of suffering serious heart problems by announcing that 2013 cases are eligible for review by our legal staff.
“In reviewing the increasing volume of consumer inquiries that we have received about allegations involving links outlined by the FDA between Zithromax and the possibility of serious side effects many questions have been asked about legal time limits,” said Resource4thePeople.
“To clarify the situation, 2013 cases as well as previous cases from consumers are eligible for review by our nationwide team of network who are offering free consultations to consumers about the legal options in their cases.”
Resource4thePeople said that the eligibility extends to past and current patients who allegedly suffered serious side effects as a result of their use of the popular antibiotic Zithromax, which is also sold as azithromycin or as the Z-Pak.
The increase in consumer inquiries came after concerns about side effects from the antibiotics were issued recently by the Food and Drug Administration* and a respected medical journal** about whether patients who use the medications are at higher risk of suffering cardiac problems, said Resource4thePeople.
“We want to inform consumers that we have now increased the number of members of our legal staff investigating claims of health problems caused by the use of the antibiotics sold as Zithromax, the Z-Pak and azithromycin,” said Resource4thePeople.
“Our experienced national network of attorneys will continue to offer free consultations to those consumers seeking to determine whether they are eligible to file a Zithromax lawsuit.
“We will be able to provide the legal options that may be available, depending upon the facts of each case, for consumers to seek compensation for such expenses as medical costs, pain and suffering, loss of wages and other expenses that may have been incurred.”
Resource4thePeople said this impetus for this increase in legal inquiries comes after the FDA issued a Safety Information Report* “on risk of cardiovascular death” in connection with the use of Zithromax.
In that report, FDA officials said that they have been made aware of a study** published in the New England Journal of Medicine in which medical researchers found a higher percentage of cardiovascular deaths among patients treated with azithromycin (Zithromax) than with other antibiotics or no drugs.
The FDA announced that it is reviewing the findings of this study and said it will inform health care professionals and consumers about the results of this review after its completion.
The FDA also passed on this information about the review and updated warnings on the medication’s labels about health risks:
“Azithromycin belongs to a class of antibacterial drugs called macrolides, which have been associated with cardiovascular effects; specifically, prolongation of the QT interval. In 2011, FDA reviewed macrolide drug labeling information related to QT interval prolongation and TdP.
“The WARNINGS AND PRECAUTIONS section of the Zmax drug label (azithromycin extended release for oral suspension) was revised in March 2012 to include new information regarding risk for QT interval prolongation, which appears to be low.
“The drug labels for clarithromycin and erythromycin also contain information about QT interval prolongation in the WARNINGS section. FDA is in the process of updating risk information in the drug labels for additional macrolide antibacterial drugs.”
The FDA also recommended that patients who are taking azithromycin should not stop taking their medicine without talking to their health care professional and that physicians “should be aware of the potential for QT interval prolongation and heart arrhythmias when prescribing or administering macrolides.”
“In its Safety Information Report the FDA also encouraged patients and health care professionals to report adverse events or side effects caused by the use of these medications to the agency,” said Resource4thePeople.
“While the FDA is fulfilling its role of monitoring the safety of drugs such as Zithromax we are responding to reports from patients who are seeking information about what their legal rights may be and we are committed to providing that information on a case-by-case basis.”
The New England Journal of Medicine study** included research compiled from information accumulated from about 350,000 patients who were treated with azithromycin over a 15-year period and concluded that these patients were one and a half times more likely to suffer cardiovascular sudden death than patients treated with other antibiotics.
Antibiotics are among the most prescribed medications and azithromycin is most commonly chosen by doctors to treat a variety of bacterial infections.
One of the factors that made Zithromax so popular was the fact that it could be taken as a five-day treatment while most other antibiotics are prescribed to be taken over a 10-day treatment plan.
“The fact that there were so many individuals included in this massive research study reported in the New England Journal of Medicine study and that the FDA is now reviewing this material has increased concerns by many consumers who are telling us that they were treated with this medication,” said Resource4thePeople.
“Therefore, our lawyers are now actively investigation these claims and stand ready to offer their experience in this area of the law to fully inform consumers who contact us about what facts must be proven in the filing of a Zithromax lawsuit over allegations of serious cardiovascular side effects.”